Shubhra Jain
Physician turned Investor passionate about cutting edge technologies in health and bio!
Shubhra Jain
Physician turned Investor passionate about cutting edge technologies in health and bio!
San Francisco, California
Overview
Work Experience
Head of Healthcare Investments
2022 - Current
Lead venture and growth investments in health and bio Select portfolio - Fathom - Phil - Cue - Chronus
Managing Partner
2020
Investor
2018
Investor
2018
Digital Health Council
2018
Advisor and mentor to digital health startups in the Springboard portfolio. Lending my time and network to help support and empower a new set of exciting women-led companies every year.
Global Mentor
2018
Endeavor is the only non-profit that supports high-impact entrepreneurs around the world. Our "mentor capitalist" model breaks down economic and cultural barriers to entrepreneurship through advising from our network of world-class business leaders. With their guidance, our 1600+ Endeavor Entrepreneurs throughout Latin America, Africa, the Middle East, Southeast Asia and the U.S. have created 1.5 million high-value jobs and, generate $15 billion in revenues each year, and inspire future generations of entrepreneurs to innovate and take risks.
Board Member
2018
FemTech Collective is the premiere network connecting innovators in the female focused health technology space through unique and impactful events.
Principal
2018 - 2020
Cota takes a unique and differentiated approach to investing by identifying attractive investments across private and public markets, from early-stage venture to public companies. This thematic, stage agnostic, and operationally engaged approach provides flexibility to deploy funding at the most opportunistic points within the innovation and liquidity cycles. Cota Capital is led by a strong team of investors, entrepreneurs, and company-builders, and partners with world-class entrepreneurs and leadership teams to build businesses that leverage technology in innovative ways to disrupt all industries.
Board
2018 - 2020
Mission Bio’s Tapestri® Platform provides unprecedented insight into the heterogeneity among cells that drive complex diseases like cancer, so you can map disease progression and better guide dynamic treatment.
Board
2018 - 2020
Bioniz leverages its world-class expertise in cytokine biology, originating in research conducted at the National Institutes of Health (NIH), to develop a novel approach to selectively inhibit functionally redundant cytokines by blocking their unique binding interface with their shared receptor. Through our platform, we have identified a number of product candidates that address immuno-inflammatory diseases and cancer.